Foley Hoag’s Life Sciences Coverage & Payment practice advises early stage to global leaders of drug, biological and medical device companies on a broad range of health policy matters impacting novel technologies with a particular expertise on Medicare coverage, coding and payment determinations. The group focuses on legal and regulatory matters before the Department of Health and Human Services (HHS), the Centers for Medicare & Medicaid Services (CMS), and, where relevant, the Health Resources and Services Agency (HRSA). We also closely follow health care legislative policy matters in Congress impacting the life sciences.
Attorneys in our Coverage & Payment practice provide strategic advice to help companies position new technologies in the evolving coverage and reimbursement landscape. Based on decades of experience with CMS, Congress, Medicare contractors, state Medicaid agencies, and the U.S. Food and Drug Administration (FDA), Foley Hoag has earned a reputation as a strong team of health policy experts who are focused on achieving our clients’ goals at the most appropriate decision-making level. Our extensive background informs our strategies to obtain appropriate coverage and payment for a wide range of life sciences technologies, including drugs, biologics, medical devices, molecular diagnostics, and durable medical equipment.More »